Castle Biosciences (CSTL) Cash from Operations (2018 - 2026)

Castle Biosciences (CSTL) has 9 years of Cash from Operations data on file, last reported at 22129000.0 in Q1 2026.

• Quarterly Cash from Operations fell 266.62% year-over-year to 22129000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 48254000.0 (down 26.51% YoY) and the FY2025 annual result came in at 64347000.0, down 0.8% from the prior year.
• Cash from Operations eased to 22129000.0 in Q1 2026 per CSTL's latest filing, from 26931000.0 in the prior quarter.
• The five-year high for Cash from Operations was 26931000.0 in Q4 2025, with the low at 25439000.0 in Q1 2023.
• Average Cash from Operations over 5 years is 3517823.53, with a median of 3786000.0 recorded in 2023.
• Year-over-year, Cash from Operations sank 490.2% in 2022 and surged 733.86% in 2024.
• Castle Biosciences' Cash from Operations stood at 6000000.0 in 2022, then soared by 409.78% to 18587000.0 in 2023, then jumped by 31.09% to 24365000.0 in 2024, then grew by 10.53% to 26931000.0 in 2025, then tumbled by 182.17% to 22129000.0 in 2026.
• Business Quant data shows CSTL's Cash from Operations at 22129000.0 in Q1 2026, 26931000.0 in Q4 2025, and 22631000.0 in Q3 2025.